Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric maltol in pulmonary arterial hypertension with iron deficiency anemia
jRCT2071250097Phase 2Recruiting
- Sponsor
- NeuPharma
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) and iron deficiency anemia (IDA) comparing Ferric maltol with Placebo (2 arms). Primary endpoint: Change from baseline in six-minute walk distance after 12 weeks of treatment. Started Dec 2025; status: recruiting.
02
Drugs
ferric maltol
03
Conditions
pulmonary arterial hypertension (PAH)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on jRCT2071250097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250097.